Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

X
Trial Profile

A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Doxorubicin (Primary) ; Duvelisib (Primary) ; Romidepsin (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2022 Status changed from not yet recruiting to withdrawn prior to enrolment due to safety issues with PI3 kinase inhibitors.
    • 03 Nov 2022 Planned initiation date changed to 3 Nov 2022.
    • 27 Oct 2022 Planned initiation date changed from 31 Oct 2022 to 2 Nov 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top